A new drug increases bone density and reduces the number of fractures in men fighting prostate cancer and in elderly women with bone loss, researchers report in two studies appearing August 11 in the New England Journal of Medicine. The results of these clinical trials might clear the way for approval of the drug, called denosumab, by the Food and Drug Administration.
"This certainly goes a long way toward fulfilling the criteria the FDA uses," says Sundeep Khosla of the Mayo Clinic in Rochester, Minn.
Denosumab prevents old bone from being dissolved faster than it can be replaced. While bone mineral removal and replacement is a natural balancing act, the loss of hormones -- as in postmenopausal women lacking estrogen and men with prostate cancer who are being treated with androgen-deprivation therapy -- can put it out of sync.